Gyre Therapeutics (GYRE) Other Non-Current Liabilities (2014 - 2026)

Gyre Therapeutics (GYRE) has 7 years of Other Non-Current Liabilities data on file, last reported at $2.9 million in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $2.9 million, down 15.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 million (down 15.85% YoY), and the FY2025 annual result was $1.4 million, down 86.38% from the prior year.
• Other Non-Current Liabilities rose to $2.9 million in Q1 2026 per GYRE's latest filing, from $1.4 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $12.8 million in Q4 2023 and troughed at $1.4 million in Q4 2025.
• A 4-year average of $6.3 million and a median of $4.7 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities surged 130.75% in 2024, then plunged 86.38% in 2025.
• A 4-year view of Other Non-Current Liabilities shows it stood at $12.8 million in 2023, then declined by 17.19% to $10.6 million in 2024, then sank by 86.38% to $1.4 million in 2025, then jumped by 98.34% to $2.9 million in 2026.
• Business Quant data shows GYRE's Other Non-Current Liabilities at $2.9 million in Q1 2026, $1.4 million in Q4 2025, and $3.2 million in Q3 2025.